INDUSTRY RESEARCH PRESENTATION ON

AstraZeneca India
By Dr Jaskirat Kaur Kahai Research Associate and Consultant @ Lobo Selection Services LLP

AstraZeneca plc.
AstraZeneca plc. is a British multinational pharmaceutical and biologics company headquartered in London, United Kingdom. Created in 1999 through the merger of Swedish Astra AB and British Zeneca Group plc, it is the world's seventh-largest pharmaceutical company measured by revenues and has operations in over 100 countries.

A Brief of History of AstraZeneca India

AstraZeneca is represented in India as two legal entities AstraZeneca Pharma India Limited (a listed sales and marketing organization with a strong manufacturing base in the country) and AstraZeneca India Pvt. Limited (a wholly owned subsidiary of AstraZeneca PLC engaged primarily in research). In 1987 Astra Research Centre India (ARCI) was set up in a building leased from IDL Chemicals Ltd. at Malleswaram Bangalore. In 1997 Government of India permitted Astra AB to form 100% owned company (Astra Biochemicals Pvt. Ltd ) In 1999 Astra Research Centre India was renamed AstraZeneca Research Foundation India to reflect its affiliation with the new company resulting from the merger of Astra and Zeneca. In 2001 AstraZeneca Pharma India was born, following global merger between Astra and Zeneca and becomes the first company in the world to set up a dedicated research centre to find a cure for Tuberculosis in Bangalore

A Brief of History of AstraZeneca India. Contd..

In 2008 Global sourcing office set up in India designed to meet AZ Global standards. In 2009- AstraZeneca collaborates with Jubliant Organosys on neuroscience research, discovered a drug to cure drug resistant TB and introduced nine new medicines and doubled its field force. In 2010- AstraZeneca India announced investments to modernize and increase the capacity of its manufacturing facility, teamed up with the Global Alliance for TB to find a cure for TB. Also, partnered with Medicines for Malaria Ventures to look for a cure for malaria, with Torrent Pharmaceuticals to supply branded generics in international markets and with Bristol Myers Squibb to launch a new drug to fight diabetes for Indian patients.

Management
Name D E Udwadia K S Shah Ian Brimicombe Luigi Felice La Corte Anandh Balasundaram Designation Chairman / Chair Person Director Director Director Managing Director

Global launch Director of Branded Generics Kumar Subramaniam

Lead business partner Asia Pacific Mohan P.

Chief Financial Officer Himanshu Agarwal

Director, Quality Assurance and Technical Services RV

Director Strategic Planning Gagan Singh

Director, Supply Chain VR

Director, regulatory Affairs Premnath Shenoy

Managing Director Anandh Balasundaram

Vice President Commercial Excellence GM

Vice president Human resources AM

Associate Director Human Resources DM

Vice president Legal, Chief Compliance officer NS

Vice President Marketing and sales Ganesh Nair

Director Sales and Marketing Sanjeev Panchal

National Sales Director, Primary care Vijay Salian

Sales Director North and East Zone Ranjeet Mishra

Regional Business Manager Delhi Manoj Sharma

Area Business Manager

Sales representative

Director Marketing, Rajeev Nagi

Associate Director of Marketing Manish Agrawal

Vice President Medical Regulatory and Clinical Research Paurus Irani

Vice President operations UM

Director of Chemistry and Metabolic Sciences Bheemarao Ugarkar

Associate Director Chemistry Balachandra Bandodkar

Regional Medical Affairs Director Asia Pacific Namrata B

Associate medical director Ashish Gulati , Paramjit Singh

Team Leader Medicinal Chemistry

General Manager and Group Medical head Medical services

Research Scientist Medicinal Chemistry

Senior Medical advisor

Regional Medical Advisor

Manager Medical services

Contact AstraZeneca India at

Head office and south zone - Avishkar Post box No. 2483, Off Bellary Road Hebbal, Bangalore 560 024. Tel: +91-80- 6774 8000 North Zone Office- AstraZeneca Pharma India Limited, C 146, Okhla Industrial Area, PHASE I,New Delhi- 110020.Tel +91- 011-26371588 OR +91 011-26371589 West Zone Office- 401-403 Chintamani Plaza, Mohan Studio Compound, Andheri - Kurla Road, Chakala, Andheri E, Mumbai - 400 099. Tel +91 022 - 67042596 / 28389320/ 28389302. Fax : 022 67042594. East Zone Office- FMC Fortuna, 4th flr, A-5 234/3A, AJC Bose Road, Kolkata 700 020, Ph : +91- 033 2283-7940/7941

AstraZeneca Pharma India Limited (AZPIL) is involved in both the manufacturing and marketing of medicines.
Key healthcare areas
Cardiovascular Respiratory Maternal Healthcare Oncology Infection Pain Control & Anaesthesia Gastrointestinal Diabetes

products
Betaloc, Seloken XL, Imdur, Ramace,Plendil,, Zestril, Crestor, Seloram, Vigocil, Nitract SR; Xparin, Valfect Rhinocort, Mits Linctus, Bricarex & Bricanyl, Symbicort,Clavatrol, Rhinofex Prostodin, Cerviprime, Primiprost & Partocin, Zoladex 3.6 mg, Gladis, Valenzia Arimidex, Nolvadex, Iressa, Casodex & Faslodex Meronem & Vancocin CP, Actamace, ,Enclere, Naropin Xylocaine & Sensorcaine, Diprivan Neksium Onglyza

Current Turnover of AstraZeneca India

Net Sales Other Income (Dec '11) Quarterly 153.48 1.50 (Mar '11) Yearly 594.03 6.28

PBDIT Net Profit

23.88 14.94

226.61 64.13

764.74 Unichem Labs Novartis India Wyeth Claris Life AstraZeneca Shasun Pharma Merck Indoco Remedies Ajanta Pharma Arvind Remedies Venus Remedies 742.71 635.27 624.90 592.87 567.13 524.76 485.39 456.78 362.44 356.68

Current Turnover of AstraZeneca India Contd

Balance Sheet Total Share Capital Net Worth Total Debt Net Block Investments Net Current Assets (Mar '11) (In Rs Cr) 5.00 179.69 0.00 27.46 0.01 128.30

Total Assets

179.70

 On Jul 29, 2010 , US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZenecas investigational drug ticagrelor for the reduction of thrombotic events in patients with Acute Coronary Syndromes (ACS). About BRILINTA/BRILIQUE - Ticagrelor (BRILINTA/BRILIQUE) is an investigational oral antiplatelet treatment for ACS. Ticagrelor is a directacting P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs). Ticagrelor is the first reversibly-binding oral ADP receptor antagonist.

AstraZeneca India in News

Shares in AstraZeneca Pharma India Ltd rose on March 6th 2012, following a report in the newspaper, citing two people familiar with the matter, that its parent AstraZeneca Plc was planning to delist the Indian unit and was in talks with top investment banks. 13 th March 2012- UK's AstraZeneca has partnered with India based Jubilant Life sciences and Belgium's Janssen Pharma. For Big Pharma companies, facing drying R&D pipelines and cost pressures, such an alliance could enhance R&D output, and leverage innovation outside their labs at lower costs. On 1 March 2012- AstraZeneca announced that MedImmune, its biologics arm, has received approval from the US Food and Drug Administration (FDA) for FluMist Quadrivalent (Influenza Vaccine Live, Intranasal) in the prevention of influenza. This marks the first four-strain influenza vaccine approved by the FDA.

Name of the Companies with Address and Board-line contact details Name of the Key Persons and Associations in this industry Basic organization structure of Major potential clients with names (and preferably Mob nos.) of decision makers in each company Current Turnover of these companies Nature of Business (products & services) Competitors (Classify: either Tier 1, Tier 2, Tier 3, etc, or basis product-wise, or MNC, Domestic, etc.) Branches in India and overseas No of Employees senior management, middle management, junior level Equity base financial strengths, funds raised What are the investments envisaged, Proposed growth plans Business Plans and Strategies Business pain areas that need attention. Clients and their industries Technologies working on Unique selling proposition of the company Corporate brochures, press releases, balance sheets and Annual reports No. of manufacturing facilities (if applicable)